Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma

Patients with plasmablastic lymphoma are potential participants of this research trial. Patients with a type of B-cell non-Hodgkin lymphoma (NHL) will be invited from Penn Medicine practices.

This research study is designed to test the safety of daratumumab, a drug added to the standard lymphoma treatment when given to individuals who have been diagnosed with plasmablastic lymphoma. The hope is that this study treatment may provide a new treatment option for patients with plasmablastic lymphoma, however, such a benefit cannot be guaranteed.

The following are some of the most commonly observed side effects: Fatigue or lack of energy; nausea; diarrhea; shortness of breath; feeling weak; fever; cough; cold-like symptoms (upper respiratory infection); nerve damage causing tingling, numbness, or pain; swollen hands, feet or limbs; constipation. The study drug may also cause serious reactions including: infusion related reaction, changes in blood tests, and decreases in blood cell counts. There is always the possibility that unknown risks and side effects may occur. These may be mild or very serious, and in some cases, may be very serious, long-lasting, or may never go away. There may also be a risk of death.